SCHEMBL2886218

SCHEMBL2886218

Cc1c[nH]c2nccc(Nc3ccc(N)cc3F)c12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ROCK2 O75116 10/20 0.44
CYP3A4 P08684 4/20 0.43
LIMK1 P53667 5/20 0.41
ERBB2 P04626 2/20 0.41
ROCK1 Q13464 2/20 0.41
CDC42BPA Q5VT25 2/20 0.41
CDC7 O00311 1/20 0.41
CHEK1 O14757 1/20 0.41
AURKA O14965 1/20 0.41
PDPK1 O15530 1/20 0.41
DAPK3 O43293 1/20 0.41
DYRK3 O43781 1/20 0.41
CACNA1F O60840 1/20 0.41
RAF1 P04049 1/20 0.41
NTRK1 P04629 1/20 0.41
INSR P06213 1/20 0.41
CDK1 P06493 1/20 0.41
FES P07332 1/20 0.41
CSF1R P07333 1/20 0.41
LYN P07948 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4404315 0.91 AURKA (0.37) ROCK2CYP3A4LIMK1ERBB2ROCK1
SCHEMBL2881782 0.86 ROCK2 (0.45) ROCK2CYP3A4LIMK1ERBB2ROCK1
SCHEMBL8269657 0.85 ROCK2 (0.40) ROCK2CYP3A4ERBB2ROCK1CDC42BPA
Hydrochloric Acid SCHEMBL2887834 0.85 ROCK2 (0.44) ROCK2CYP3A4LIMK1ERBB2ROCK1
SCHEMBL2890101 0.82 TBK1 (0.39) ROCK2CYP3A4LIMK1AURKACDK1
SCHEMBL2881321 0.80 CDK4 (0.41) ROCK2CYP3A4LIMK1ERBB2CDK2
SCHEMBL2881276 0.78 ROCK2 (0.71) ROCK2CYP3A4ERBB2ROCK1CDC42BPA
SCHEMBL5318403 0.77 ROCK2 (0.47) ROCK2CYP3A4LIMK1ERBB2ROCK1
SCHEMBL8272279 0.76 ROCK2 (0.56) ROCK2CYP3A4LIMK1ERBB2ROCK1
SCHEMBL2884975 0.76 ROCK2 (0.39) ROCK2CYP3A4LIMK1ERBB2ROCK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7723347-B2 Substituted phenylamino-pyrimidines BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-05-25 US disclosed
US-7723347-B2 Substituted phenylamino-pyrimidines BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-05-25 US disclosed
US-7723347-B2 Substituted phenylamino-pyrimidines BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-05-25 US disclosed
EP-1742945-B1 SUBSTITUTED PHENYLAMINO-PYRIMIDINES BAYER SCHERING PHARMA AG (DE) 2009-12-30 EP disclosed
EP-1742945-B1 SUBSTITUTED PHENYLAMINO-PYRIMIDINES BAYER SCHERING PHARMA AG (DE) 2009-12-30 EP disclosed
US-20080269268-A1 Substituted Phenylamino-Pyrimidines BAYER HEALTHCARE AG (DE) 2008-10-30 US disclosed
US-20080269268-A1 Substituted Phenylamino-Pyrimidines BAYER HEALTHCARE AG (DE) 2008-10-30 US disclosed
US-20080269268-A1 Substituted Phenylamino-Pyrimidines BAYER HEALTHCARE AG (DE) 2008-10-30 US disclosed
EP-1742945-A1 SUBSTITUTED PHENYLAMINO-PYRIMIDINES Bayer HealthCare AG (DE) 2007-01-17 EP disclosed
WO-2005108397-A1 SUBSTITUTED PHENYLAMINO-PYRIMIDINES BAYER HEALTHCARE AG (DE) 2005-11-17 WO disclosed
WO-2005108397-A1 SUBSTITUTED PHENYLAMINO-PYRIMIDINES BAYER HEALTHCARE AG (DE) 2005-11-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269268-A1 Substituted Phenylamino-Pyrimidines TYMP, DPYD, HPRT1 ROCK2 4593/4885CYP3A4 599/4885LIMK1 3751/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.